WCFF Events – ScanScor

ScanScor WCFF Events

Total Events 1797

Fish Alarms 742

Chart Now 867

UP / DOWN / UNCERTAIN 286 / 362 / 1149

Max Repricing 99%

Max Fade Risk 99%

Created	Ticker	Direction	Alarm	Type	Risk	Headline	Reason
2026-06-26 22:00:42 Story: 2026-06-26 18:00:00	ADMA ID 1797	DOWN Up 5% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 8% Fade: 92% Thesis Break: 12% Today: 8.55 - 8.90	ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm Parse: PARSED	Repeat plaintiff-lawyer lawsuit notice is stale, non-corporate news and usually adds little new repricing pressure after initial disclosure. Input: ADEQUATE - Recent headline history clearly shows this lawsuit alert is repetitive and already in the market.
2026-06-26 21:16:58 Story: 2026-06-26 17:15:00	MTNB ID 1796	DOWN Up 8% / Down 68%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN COMPLIANCE GlobeNewswire RSS	Reprice: 54% Fade: 72% Thesis Break: 66% Today: 0.58 - 0.67	Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance Parse: PARSED	Accepted compliance plan avoids immediate delisting, but repeated equity deficiency notice reinforces financing and delisting overhang for a fragile microcap. Input: ADEQUATE - Fresh notice, prior similar notice, tiny market cap, and recent financing context are sufficient to assess near-term downside repricing risk.
2026-06-26 20:31:13 Story: 2026-06-26 16:30:00	NKTR ID 1795	UNCERTAIN Up 6% / Down 8%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 5% Fade: 88% Thesis Break: 2% Today: 62.20 - 64.50	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Parse: PARSED	Routine inducement grant disclosure is non-catalytic, tiny versus share count, and recently repeated with no new clinical, regulatory, or financing signal. Input: ADEQUATE - Story context is sufficient to classify this as routine compensation news with minimal standalone repricing relevance.
2026-06-26 20:16:57 Story: 2026-06-26 16:15:00	CBIO ID 1794	UNCERTAIN Up 6% / Down 8%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 9% Fade: 88% Thesis Break: 4% Today: 17.60 - 18.60	Crescent Biopharma Announces Grants of Inducement Awards Parse: PARSED	Inducement option grants are routine, repeated, and non-catalytic, with little reason for durable repricing despite any brief low-quality volume response. Input: ADEQUATE - Story, trading context, and repeated prior inducement headlines are sufficient to classify this as non-actionable routine news.
2026-06-26 20:16:47 Story: 2026-06-26 16:15:00	NEUP ID 1793	UP Up 72% / Down 28%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_UP OTHER GlobeNewswire RSS	Reprice: 81% Fade: 67% Thesis Break: 58% Today: 4.25 - 5.40	Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc Parse: PARSED	Confirmed acquisition talks can reprice this tiny float strategic-review biotech, but nonbinding deal language makes any spike vulnerable to fading. Input: ADEQUATE - Fresh confirmation of active combination talks plus float and market-cap context are sufficient for short-term event-reaction assessment.
2026-06-26 20:07:02 Story: 2026-06-26 16:05:00	MNPR ID 1792	UNCERTAIN Up 42% / Down 18%	Fish: NO Chart: YES MEDIUM	WATCH_CHART CLINICAL_DATA GlobeNewswire RSS	Reprice: 34% Fade: 78% Thesis Break: 12% Today: 84.00 - 92.00	Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease Parse: PARSED	Positive Phase 3 follow-up analyses support NDA timing, but this appears largely incremental to prior data and conference presentations. Input: ADEQUATE - Recent headline history shows similar neurologic-benefit disclosures, limiting novelty despite supportive late-stage clinical framing.
2026-06-26 20:02:33 Story: 2026-06-26 16:01:00	ASND ID 1791	UNCERTAIN Up 28% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 24% Fade: 72% Thesis Break: 4% Today: 254.00 - 263.00	Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap® Parse: PARSED	Russell index inclusion is largely mechanical, expected, and usually creates limited durable repricing for a liquid large-cap biotech. Input: ADEQUATE - Story and market context are sufficient; no additional filings or clinical context are needed for this event-reaction call.
2026-06-26 18:50:46 Story: 2026-06-26 14:49:00	RCKT ID 1790	UNCERTAIN Up 2% / Down 1%	Fish: NO Chart: NO HIGH	IGNORE OTHER GlobeNewswire RSS	Reprice: 3% Fade: 95% Thesis Break: 1% Today: 3.08 - 3.16	Rocket Lab Completes 10th Consecutive Launch with 100% Mission Success for Synspective Parse: PARSED	Story is about Rocket Lab RKLB, not Rocket Pharmaceuticals RCKT, so it is irrelevant ticker-noise. Input: ADEQUATE - Headline-body mismatch versus company info is clear enough to dismiss without further catalyst analysis.
2026-06-26 18:46:20 Story: 2026-06-26 14:45:00	ERAS ID 1789	DOWN Up 5% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 8% Fade: 92% Thesis Break: 20% Today: 14.70 - 15.40	Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit Parse: PARSED	Repeat class-action solicitation is stale legal-ad noise, not a fresh operational catalyst, though it mildly reinforces existing overhang. Input: ADEQUATE - Recent headline history clearly shows this lawsuit alert is repetitive and already public.
2026-06-26 18:24:23 Story: 2026-06-26 14:24:00	TECH ID 1788	UNCERTAIN Up 5% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 8% Fade: 85% Thesis Break: 6% Today: 69.50 - 71.23	SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bio-Techne Corporation (NASDAQ: TECH) Parse: PARSED	Merger-law-firm investigation headlines are common post-deal noise and rarely alter pricing unless they signal a real bid break or revised terms. Input: ADEQUATE - Context is sufficient because the underlying Merck acquisition was already disclosed and this alert adds no new economic terms.
2026-06-26 15:01:22 Story: 2026-06-26 11:00:00	APLT ID 1787	UNCERTAIN Up 4% / Down 6%	Fish: NO Chart: NO HIGH	IGNORE OTHER PRNewswire RSS	Reprice: 8% Fade: 85% Thesis Break: 5% Today: -	Applied ABC Launches "Mahalo ABA" in Hawaii, Bringing Clinically Led Autism Services to Children Across the Islands Parse: PARSED	Story appears unrelated to Applied Therapeutics and describes routine service expansion, not a biotech catalyst for APLT. Input: TOO_MUCH_NOISE - Ticker-news match looks contaminated by another Applied-branded company, limiting event relevance assessment.
2026-06-26 15:01:18 Story: 2026-06-26 11:00:00	CPIX ID 1786	UNCERTAIN Up 58% / Down 42%	Fish: YES Chart: YES MEDIUM	WATCH_CHART CLINICAL_DATA PRNewswire RSS	Reprice: 61% Fade: 78% Thesis Break: 64% Today: 5.75 - 6.55	Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference Parse: PARSED	Updated Phase 2 biomarker data is supportive but largely incremental conference follow-up, making any spike vulnerable to fade. Input: ADEQUATE - Story includes enough clinical and market context to judge this as incremental data rather than a clearly new pivotal catalyst.
2026-06-26 14:26:28 Story: 2026-06-26 10:25:00	GPCR ID 1785	UNCERTAIN Up 1% / Down 1%	Fish: NO Chart: NO HIGH	IGNORE OTHER PRNewswire RSS	Reprice: 1% Fade: 0% Thesis Break: 0% Today: 48.50 - 49.50	Infrastructure Capital announces a dividend increase for The Infrastructure Capital Nasdaq Option Income ETF (QVOL) Parse: PARSED	This PR is about an unrelated ETF dividend and has no catalyst relevance to Structure Therapeutics. Input: ADEQUATE - Ticker-news mismatch is clear, so no biotech event-reaction signal is created here.
2026-06-26 14:07:58 Story: 2026-06-26 10:07:00	IPSC ID 1784	UNCERTAIN Up 1% / Down 1%	Fish: NO Chart: NO HIGH	IGNORE OTHER PRNewswire RSS	Reprice: 1% Fade: 95% Thesis Break: 0% Today: 2.28 - 2.45	AVANTIS INVESTORS REACHES $150 BILLION IN ASSETS UNDER MANAGEMENT IN LESS THAN SEVEN YEARS Parse: PARSED	Story is unrelated to Century Therapeutics and provides no company-specific biotech catalyst or repricing signal for IPSC. Input: ADEQUATE - Headline-body mismatch is clear; this is third-party asset-management news, not actionable IPSC news.
2026-06-26 13:44:03 Story: 2026-06-26 09:42:00	CRIS ID 1783	DOWN Up 22% / Down 74%	Fish: YES Chart: YES HIGH	STRAY_WILDCAT_DOWN COMPLIANCE PRNewswire RSS	Reprice: 71% Fade: 81% Thesis Break: 88% Today: 0.17 - 0.27	Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split Parse: PARSED	Reverse split approval and disclosed sub-12-month cash runway outweigh routine enrollment progress, creating near-term downside and dilution-sensitive repricing risk. Input: ADEQUATE - Story includes the key catalyst, cash warning, compliance context, and enough price history for event-reaction assessment.
2026-06-26 13:30:55 Story: 2026-06-26 09:30:00	HELP ID 1782	UNCERTAIN Up 38% / Down 22%	Fish: NO Chart: YES HIGH	WATCH_CHART OTHER PRNewswire RSS	Reprice: 34% Fade: 82% Thesis Break: 28% Today: 5.75 - 6.45	A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year Parse: PARSED	Paid promotional rehash of a two-day-old enrollment update after financing, with no new clinical data, creates attention but likely pop-and-fade risk. Input: ADEQUATE - News timing, prior company release, financing context, and trading setup are sufficient to judge this as low-quality catalyst noise.
2026-06-26 13:16:48 Story: 2026-06-26 09:15:00	IRD ID 1781	UNCERTAIN Up 38% / Down 22%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 34% Fade: 78% Thesis Break: 8% Today: 3.58 - 3.95	Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes Parse: PARSED	Russell inclusion can create brief index-flow support, but this is usually a known, low-durability catalyst without fundamental change. Input: ADEQUATE - Enough context exists to judge this as routine index-reconstitution news with limited standalone repricing power.
2026-06-26 13:10:21 Story: 2026-06-26 09:10:00	ANIX ID 1780	UP Up 68% / Down 32%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_UP CLINICAL_DATA PRNewswire RSS	Reprice: 61% Fade: 78% Thesis Break: 57% Today: 2.48 - 3.05	Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium Parse: PARSED	Fresh Phase 1 clinical data can spark upside attention, but symposium-presented early data in a tiny biotech carries strong pop-and-fade risk. Input: ADEQUATE - News, market cap, liquidity, prior related headlines, and insider context are sufficient for short-horizon event-reaction assessment.
2026-06-26 13:06:58 Story: 2026-06-26 09:05:00	CAPR ID 1779	UNCERTAIN Up 42% / Down 18%	Fish: YES Chart: YES HIGH	WATCH_CHART CLINICAL_DATA GlobeNewswire RSS	Reprice: 46% Fade: 74% Thesis Break: 20% Today: 29.10 - 32.80	Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference Parse: PARSED	Positive OLE durability data supports the DMD story, but much of the Phase 3 catalyst was previously disclosed and conference presentations often fade. Input: ADEQUATE - Fresh headline, prior catalyst context, short interest, and valuation setup are sufficient for event-reaction assessment.
2026-06-26 13:01:30 Story: 2026-06-26 09:00:00	COAG ID 1778	UNCERTAIN Up 42% / Down 24%	Fish: YES Chart: YES MEDIUM	WATCH_CHART CLINICAL_DATA GlobeNewswire RSS	Reprice: 38% Fade: 72% Thesis Break: 18% Today: 26.80 - 30.50	Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress Parse: PARSED	Fresh human and pipeline data add credibility, but this is conference-preview news with limited immediate surprise and elevated fade risk. Input: ADEQUATE - Enough context exists to judge this as watchlist-worthy, though actual abstract details and cash runway precision would improve confidence.
2026-06-26 12:57:05 Story: 2026-06-26 08:55:00	HCWB ID 1777	DOWN Up 12% / Down 74%	Fish: YES Chart: YES HIGH	STRAY_WILDCAT_DOWN COMPLIANCE GlobeNewswire RSS	Reprice: 71% Fade: 83% Thesis Break: 68% Today: 0.95 - 1.20	HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 Parse: PARSED	Reverse split to satisfy Nasdaq panel signals distress and often pressures fragile microcaps despite preserving listing status. Input: ADEQUATE - Fresh reverse-split compliance news plus weak balance sheet and recent financing provide enough context for event-reaction assessment.
2026-06-26 12:46:04 Story: 2026-06-26 08:45:00	NKTX ID 1776	UNCERTAIN Up 8% / Down 6%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 10% Fade: 78% Thesis Break: 4% Today: 2.68 - 2.92	Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference Parse: PARSED	Conference participation is routine and lacks new clinical, regulatory, financing, or partnership substance likely to drive meaningful repricing. Input: ADEQUATE - Story is clear and recent, and context strongly indicates a standard investor-conference announcement.
2026-06-26 12:31:54 Story: 2026-06-26 08:30:00	CDT ID 1775	UNCERTAIN Up 18% / Down 42%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 22% Fade: 92% Thesis Break: 88% Today: 0.62 - 0.95	CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form Development Parse: PARSED	Promotional platform-update news lacks concrete revenue, clinical, regulatory, or financing catalyst and fits prior low-quality microcap hype pattern. Input: ADEQUATE - News, price action, float, and recent financing/compliance context are sufficient to judge this as non-actionable routine promotion.
2026-06-26 12:31:47 Story: 2026-06-26 08:30:00	LIXT ID 1774	UNCERTAIN Up 34% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 29% Fade: 82% Thesis Break: 71% Today: 6.10 - 7.25	LIXTE Joins Russell Microcap Index Parse: PARSED	Russell Microcap inclusion is routine index news and usually not a durable catalyst for a volatile story-driven microcap. Input: ADEQUATE - Fresh headline, price history, and recent financing context are sufficient to judge this as low-urgency routine news.
2026-06-26 12:02:30 Story: 2026-06-26 08:00:00	REPL ID 1773	UP Up 78% / Down 22%	Fish: YES Chart: YES HIGH	STRAY_WILDCAT_UP REGULATORY GlobeNewswire RSS	Reprice: 88% Fade: 58% Thesis Break: 41% Today: 10.60 - 12.80	Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma Parse: PARSED	FDA accepted the RP1 BLA resubmission, set a near-term August PDUFA, and flagged an adcom, creating immediate regulatory repricing attention. Input: ADEQUATE - Fresh regulatory acceptance, prior CRL context, heavy short interest, and recent volatility provide enough context for event-reaction assessment.
2026-06-26 12:01:24 Story: 2026-06-26 08:01:00	AEMD ID 1772	UNCERTAIN Up 38% / Down 22%	Fish: YES Chart: YES MEDIUM	WATCH_CHART PRECLINICAL PRNewswire RSS	Reprice: 41% Fade: 88% Thesis Break: 79% Today: 0.82 - 1.18	Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier® Parse: PARSED	Peer-reviewed biomarker publication may spark a speculative bounce, but it lacks near-term clinical, regulatory, or financing substance. Input: ADEQUATE - News, price collapse, float, and financing context are sufficient to judge this as a likely low-quality pop-and-fade setup.
2026-06-26 12:01:14 Story: 2026-06-26 08:00:00	VXRT ID 1771	UNCERTAIN Up 12% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 14% Fade: 88% Thesis Break: 20% Today: 0.49 - 0.53	Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY Parse: PARSED	Proxy-fight solicitation repeats prior messaging and lacks new clinical, financing, regulatory, or partnership substance likely to drive durable repricing. Input: ADEQUATE - News context clearly shows this is repeated proxy-contest communication rather than a fresh operational catalyst.
2026-06-26 11:32:07 Story: 2026-06-26 07:30:00	VANI ID 1770	UNCERTAIN Up 8% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 10% Fade: 85% Thesis Break: 5% Today: 1.10 - 1.18	Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker Parse: PARSED	Board appointment and retirement are routine governance changes without concrete clinical, regulatory, financing, or partnership catalyst. Input: ADEQUATE - Fresh headline, price context, and recent catalyst history are sufficient to judge this as low-urgency routine news.
2026-06-26 11:02:59 Story: 2026-06-26 07:00:00	FTRE ID 1769	UNCERTAIN Up 28% / Down 24%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 31% Fade: 72% Thesis Break: 18% Today: 16.95 - 18.25	Fortrea Names Jason Knoblauch as Chief Financial Officer Parse: PARSED	CFO transition with reiterated guidance is routine management news, not a concrete operating catalyst likely to drive durable repricing. Input: ADEQUATE - Story, price context, and guidance language are sufficient to classify this as low-urgency routine news.
2026-06-26 11:02:52 Story: 2026-06-26 07:00:00	CANF ID 1768	UNCERTAIN Up 38% / Down 18%	Fish: YES Chart: YES MEDIUM	WATCH_CHART REGULATORY GlobeNewswire RSS	Reprice: 41% Fade: 86% Thesis Break: 22% Today: 2.82 - 3.35	Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology Parse: PARSED	Japanese patent allowance is incremental IP news, not near-term revenue or clinical data, but tiny CANF can still see a brief obesity-theme spike. Input: ADEQUATE - News, market cap, price history, and recent context are sufficient to judge this as likely low-quality catalyst-driven volatility.
2026-06-26 11:01:42 Story: 2026-06-26 07:00:00	AXSM ID 1767	UNCERTAIN Up 28% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 24% Fade: 72% Thesis Break: 8% Today: 232.00 - 244.00	Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) Parse: PARSED	Phase 3 first-patient-dosed news adds pipeline progress but lacks data, approval, partnership, or near-term value inflection. Input: ADEQUATE - Story context and company setup are sufficient to judge this as low-urgency pipeline progression news.
2026-06-26 11:01:37 Story: 2026-06-26 07:00:00	AVTX ID 1766	UNCERTAIN Up 38% / Down 18%	Fish: NO Chart: YES HIGH	WATCH_CHART OTHER GlobeNewswire RSS	Reprice: 34% Fade: 72% Thesis Break: 8% Today: 17.20 - 18.90	Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes Parse: PARSED	Russell inclusion can create brief passive-flow support, but it is a routine index event with limited standalone biotech catalyst value. Input: ADEQUATE - News, price action, short interest, and recent financing context are sufficient to judge this as monitor-only.
2026-06-26 11:01:32 Story: 2026-06-26 07:00:00	JBIO ID 1765	UNCERTAIN Up 8% / Down 6%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 12% Fade: 78% Thesis Break: 4% Today: 21.10 - 22.40	Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors Parse: PARSED	Board appointment is routine governance news without clinical, regulatory, financing, or partnership substance to drive meaningful repricing. Input: ADEQUATE - News, recent catalyst history, financing context, and trading profile are sufficient to judge this as low-urgency routine news.
2026-06-26 11:00:26 Story: 2026-06-26 07:00:00	CPRX ID 1764	UNCERTAIN Up 1% / Down 1%	Fish: NO Chart: NO HIGH	IGNORE OTHER PRNewswire RSS	Reprice: 1% Fade: 0% Thesis Break: 0% Today: 31.30 - 31.50	Catalyst Bancorp, Inc. and Lakeside Bancshares, Inc. Announce Shareholder and Regulatory Approvals for Pending Mergers Parse: PARSED	Story is about bank ticker CLST, not Catalyst Pharmaceuticals CPRX, so it is non-actionable ticker confusion. Input: ADEQUATE - Headline and body clearly identify a different company, making this a false match rather than a CPRX catalyst.
2026-06-26 10:01:21 Story: 2026-06-26 06:00:00	IDYA ID 1763	UNCERTAIN Up 6% / Down 8%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 9% Fade: 78% Thesis Break: 3% Today: 35.60 - 36.80	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Parse: PARSED	Routine inducement grant for new hires is non-catalytic, tiny versus float, and unlikely to change valuation or near-term sentiment. Input: ADEQUATE - News, price context, and recent financing history are sufficient to classify this as low-urgency routine corporate disclosure.
2026-06-26 08:00:35 Story: 2026-06-25 23:58:00	NUVB ID 1762	DOWN Up 18% / Down 78%	Fish: YES Chart: YES HIGH	STRAY_WILDCAT_DOWN FINANCING PRNewswire RSS	Reprice: 84% Fade: 62% Thesis Break: 34% Today: 5.35 - 6.05	Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes Parse: PARSED	Upsized convertible notes usually pressure biotech shares via dilution overhang, hedge-related selling, and signal financing urgency despite debt repayment benefits. Input: ADEQUATE - Fresh financing terms, market cap, short interest, and price context are sufficient for an event-reaction judgment.
2026-06-25 22:42:25 Story: 2026-06-25 18:41:00	CORT ID 1761	DOWN Up 8% / Down 34%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 22% Fade: 78% Thesis Break: 18% Today: 81.00 - 85.50	Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm Parse: PARSED	Shareholder-law-firm investigation notices usually add little new information and rarely create durable repricing without fresh regulatory facts. Input: ADEQUATE - Context is sufficient; this appears derivative of already known relacorilant FDA issues and NDA resubmission history.
2026-06-25 20:31:15 Story: 2026-06-25 16:30:00	CLLS ID 1760	UNCERTAIN Up 8% / Down 10%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 12% Fade: 85% Thesis Break: 5% Today: 2.78 - 2.95	Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 Parse: PARSED	Shareholder meeting vote results are routine governance news with no clear catalyst, financing change, or regulatory impact. Input: ADEQUATE - Story details are sufficient to classify this as non-actionable routine corporate governance news.
2026-06-25 20:15:59 Story: 2026-06-25 16:15:00	EIKN ID 1759	UNCERTAIN Up 38% / Down 18%	Fish: NO Chart: YES MEDIUM	WATCH_CHART OTHER GlobeNewswire RSS	Reprice: 34% Fade: 78% Thesis Break: 8% Today: 9.45 - 10.40	Eikon Therapeutics to Join the Russell 3000® Index Parse: PARSED	Russell 3000 inclusion can create brief passive-flow support, but it is routine index news with limited standalone biotech catalyst value. Input: ADEQUATE - Enough context to judge this as likely technical flow news rather than a fundamental repricing catalyst.
2026-06-25 20:12:43 Story: 2026-06-25 16:10:00	RCKT ID 1758	UNCERTAIN Up 2% / Down 1%	Fish: NO Chart: NO HIGH	IGNORE OTHER GlobeNewswire RSS	Reprice: 1% Fade: 0% Thesis Break: 0% Today: 3.24 - 3.24	NASA Selects Rocket Lab to Launch Sun, Earth Sciences Missions Parse: PARSED	Story is for Rocket Lab RKLB, not Rocket Pharmaceuticals RCKT, so it is irrelevant ticker-mismatch noise. Input: ADEQUATE - Ticker-company mismatch is clear from the article body naming Rocket Lab and Nasdaq: RKLB.
2026-06-25 20:11:32 Story: 2026-06-25 16:10:00	QURE ID 1757	DOWN Up 18% / Down 74%	Fish: YES Chart: YES HIGH	STRAY_WILDCAT_DOWN FINANCING GlobeNewswire RSS	Reprice: 71% Fade: 63% Thesis Break: 28% Today: 45.00 - 50.50	uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares Parse: PARSED	Closing an upsized offering with full greenshoe confirms dilution after a sharp run, creating near-term downside repricing and overhang risk. Input: ADEQUATE - News, pricing context, recent catalyst history, and market structure are sufficient for an event-reaction judgment.
2026-06-25 20:06:00 Story: 2026-06-25 16:05:00	REGN ID 1756	UNCERTAIN Up 5% / Down 5%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS EARNINGS GlobeNewswire RSS	Reprice: 8% Fade: 2% Thesis Break: 1% Today: 617.00 - 626.00	Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast Parse: PARSED	Routine earnings date announcement lacks new financial, clinical, or regulatory information and is unlikely to drive immediate repricing. Input: ADEQUATE - Story is clear and sufficient because it only announces a scheduled earnings release and webcast.
2026-06-25 20:02:42 Story: 2026-06-25 16:01:00	ASND ID 1755	UNCERTAIN Up 28% / Down 14%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS CLINICAL_DATA GlobeNewswire RSS	Reprice: 22% Fade: 72% Thesis Break: 8% Today: 255.00 - 266.00	Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 Parse: PARSED	Conference presentation notice with follow-up data, but no fresh topline release or regulatory catalyst, so incremental impact looks limited. Input: ADEQUATE - Story, price action, prior related headlines, and company context are sufficient to judge this as low-urgency conference news.
2026-06-25 20:02:36 Story: 2026-06-25 16:01:00	KROS ID 1754	UNCERTAIN Up 8% / Down 6%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 10% Fade: 85% Thesis Break: 2% Today: 10.20 - 10.70	Keros Therapeutics Appoints Anne Prener to its Board of Directors Parse: PARSED	Board appointment is routine governance news with no clinical, regulatory, financing, or partnership catalyst to drive meaningful near-term repricing. Input: ADEQUATE - Story context and trading setup are sufficient; no additional filings appear necessary for this event-reaction judgment.
2026-06-25 20:02:30 Story: 2026-06-25 16:01:00	LGND ID 1753	DOWN Up 20% / Down 58%	Fish: NO Chart: YES MEDIUM	WATCH_CHART FINANCING GlobeNewswire RSS	Reprice: 34% Fade: 72% Thesis Break: 22% Today: 286.00 - 302.00	Ligand Announces Closing of Convertible Senior Notes Offering Parse: PARSED	Closing a large convertible notes deal is mostly expected financing overhang, mildly dilutive and not a fresh business catalyst. Input: ADEQUATE - News, prior offering context, price trend, and capital structure details are sufficient for an event-reaction judgment.
2026-06-25 19:18:49 Story: 2026-06-25 15:17:00	OLMA ID 1752	UNCERTAIN Up 1% / Down 1%	Fish: NO Chart: NO HIGH	IGNORE OTHER PRNewswire RSS	Reprice: 0% Fade: 0% Thesis Break: 0% Today: 11.15 - 11.35	Coleman Law Files Nationwide Class Action Against Rivian Over Promised Self-Driving Capabilities Parse: PARSED	Story concerns Rivian, not Olema, so it has no actionable catalyst relevance for OLMA. Input: ADEQUATE - Ticker-news mismatch is clear enough to classify this item as irrelevant noise for OLMA.
2026-06-25 15:47:11 Story: 2026-06-25 11:45:00	VALN ID 1751	UNCERTAIN Up 8% / Down 6%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 10% Fade: 78% Thesis Break: 4% Today: 5.05 - 5.28	Valneva Announces Successful Outcome of its Annual General Meeting Parse: PARSED	AGM approvals and board chair change are routine governance items without a concrete clinical, regulatory, or financing catalyst. Input: ADEQUATE - Story content is sufficient to classify this as low-urgency governance news with limited immediate repricing relevance.
2026-06-25 15:36:15 Story: 2026-06-25 11:35:00	DRTS ID 1750	UNCERTAIN Up 28% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 22% Fade: 82% Thesis Break: 12% Today: 10.35 - 11.20	Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet Parse: PARSED	DRTS is only mentioned in another company’s shareholder letter, with no new DRTS-specific clinical, regulatory, or financing catalyst. Input: ADEQUATE - Context is sufficient to judge this as indirect, non-primary-source mention rather than actionable DRTS news.
2026-06-25 14:17:21 Story: 2026-06-25 10:17:00	IPSC ID 1749	UNCERTAIN Up 1% / Down 1%	Fish: NO Chart: NO HIGH	IGNORE OTHER PRNewswire RSS	Reprice: 1% Fade: 0% Thesis Break: 0% Today: 2.33 - 2.36	MARKETS MAY BE UNDERPRICING RISK Parse: PARSED	Story is unrelated macro commentary from American Century, not Century Therapeutics company-specific news or a biotech catalyst. Input: TOO_MUCH_NOISE - Ticker-news match is false positive from name overlap, so this item should be filtered out.
2026-06-25 14:00:51 Story: 2026-06-25 10:00:00	ELTX ID 1748	DOWN Up 8% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 12% Fade: 92% Thesis Break: 96% Today: 3.45 - 4.15	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX Parse: PARSED	Law firm investigation is a common follow-on headline after the June 15 clinical failure and usually adds little new repricing pressure. Input: ADEQUATE - Freshness is adequate, and recent clinical miss context makes this investigation headline low incremental value.
2026-06-25 13:30:14 Story: 2026-06-25 09:27:00	HELP ID 1747	DOWN Up 28% / Down 72%	Fish: YES Chart: YES HIGH	STRAY_WILDCAT_DOWN FINANCING GlobeNewswire RSS	Reprice: 74% Fade: 67% Thesis Break: 31% Today: 4.70 - 5.35	Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering Parse: PARSED	Closing a large underwritten equity offering at $4.85 is dilutive and often caps near-term upside despite improved cash runway. Input: ADEQUATE - Fresh financing terms, pricing, market cap, volume, and recent catalyst context are sufficient for short-horizon event-reaction assessment.
2026-06-25 13:20:27 Story: 2026-06-25 09:20:00	NRSN ID 1746	UP Up 68% / Down 32%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_UP CLINICAL_DATA PRNewswire RSS	Reprice: 74% Fade: 84% Thesis Break: 79% Today: 0.70 - 0.98	NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease Parse: PARSED	Positive human biomarker data can spark microcap repricing, but only three analyzable patients make this highly fragile and fade-prone. Input: ADEQUATE - Enough context exists to judge this as actionable chart news despite very limited clinical sample size.
2026-06-25 13:17:01 Story: 2026-06-25 09:15:00	ERNA ID 1745	UNCERTAIN Up 8% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 10% Fade: 92% Thesis Break: 5% Today: 5.95 - 6.80	Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients Parse: PARSED	CEO Corner launch is promotional communications news, not a concrete clinical, regulatory, financing, or partnership catalyst. Input: ADEQUATE - Story and context are sufficient to classify this as non-actionable routine investor-facing news.
2026-06-25 13:06:57 Story: 2026-06-25 09:05:00	DARE ID 1744	UNCERTAIN Up 24% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 21% Fade: 82% Thesis Break: 28% Today: 2.00 - 2.22	Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment Parse: PARSED	Investor-segment promotion reiterates previously announced June launch without new sales data, approval, partnership, or financing catalyst. Input: ADEQUATE - Recent context clearly shows this is follow-on promotional news, not a fresh fundamental catalyst.
2026-06-25 13:02:31 Story: 2026-06-25 09:00:00	AARD ID 1743	DOWN Up 8% / Down 18%	Fish: NO Chart: NO HIGH	IGNORE OTHER PRNewswire RSS	Reprice: 6% Fade: 92% Thesis Break: 96% Today: 4.40 - 5.15	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS Parse: PARSED	Repeat shareholder-lawyer investigation headline adds little new information after the prior clinical hold and safety-driven collapse. Input: ADEQUATE - Recent headline history clearly shows this is recycled legal-solicitation noise, not a fresh operating catalyst.
2026-06-25 13:02:23 Story: 2026-06-25 09:00:00	MIST ID 1742	UNCERTAIN Up 18% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 14% Fade: 72% Thesis Break: 8% Today: 1.22 - 1.33	Milestone Scientific Strengthens Board to Support Next Phase of Growth Parse: PARSED	Board changes and founder agreement restructuring lack a concrete operating, clinical, regulatory, or financing catalyst for immediate repricing. Input: ADEQUATE - News details are sufficient; no clear catalyst signal emerges beyond routine governance updates.
2026-06-25 12:32:36 Story: 2026-06-25 08:30:00	CNXU ID 1741	UNCERTAIN Up 18% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 20% Fade: 78% Thesis Break: 8% Today: 10.10 - 11.40	Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform Parse: PARSED	Facility opening is operational branding, not a concrete clinical, regulatory, financing, or partnership catalyst likely to drive durable repricing. Input: ADEQUATE - News and market context are sufficient; this appears non-catalytic despite microcap volatility and recent promotional-style updates.
2026-06-25 12:16:17 Story: 2026-06-25 08:15:00	BRTX ID 1740	UNCERTAIN Up 38% / Down 24%	Fish: NO Chart: YES MEDIUM	WATCH_CHART OTHER GlobeNewswire RSS	Reprice: 41% Fade: 82% Thesis Break: 18% Today: 0.36 - 0.48	BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform Parse: PARSED	Manufacturing completion is a modest operational milestone, but not new efficacy, regulatory, or financing news, so any spike likely fades. Input: ADEQUATE - News, price history, and recent catalyst context are sufficient to judge this as low-grade event reaction risk.
2026-06-25 12:09:39 Story: 2026-06-25 08:08:00	MAIA ID 1739	UNCERTAIN Up 38% / Down 18%	Fish: YES Chart: YES MEDIUM	WATCH_CHART OTHER GlobeNewswire RSS	Reprice: 44% Fade: 72% Thesis Break: 20% Today: 1.31 - 1.58	MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer Parse: PARSED	Enrollment completion is a real clinical milestone, but without new efficacy data it is more likely a speculative pop than durable repricing. Input: ADEQUATE - Recent financing, insider buying, and prior trial updates provide enough context to judge this as monitor-worthy but not thesis-changing.
2026-06-25 12:07:21 Story: 2026-06-25 08:05:00	CADL ID 1738	UNCERTAIN Up 28% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 24% Fade: 78% Thesis Break: 10% Today: 8.95 - 9.65	Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer Parse: PARSED	Executive hire signals launch prep but adds no new clinical, regulatory, financing, or partnership catalyst beyond already disclosed commercialization plans. Input: ADEQUATE - Story context, recent catalyst history, short interest, and price setup are sufficient to judge this as low-urgency routine news.
2026-06-25 12:05:11 Story: 2026-06-25 08:04:00	QNTM ID 1737	UNCERTAIN Up 5% / Down 8%	Fish: NO Chart: NO HIGH	IGNORE OTHER PRNewswire RSS	Reprice: 12% Fade: 85% Thesis Break: 10% Today: 3.65 - 4.15	Quantum Space Appoints Adarsh Parekh as Chief Financial Officer Parse: PARSED	Story appears misattributed to biotech ticker QNTM and is only a CFO appointment, not a concrete catalyst for Quantum BioPharma. Input: ADEQUATE - Headline and body reference Quantum Space/IPFX, not Quantum BioPharma, making this non-actionable ticker noise.
2026-06-25 12:01:50 Story: 2026-06-25 08:00:00	VXRT ID 1736	UP Up 62% / Down 28%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_UP FINANCING GlobeNewswire RSS	Reprice: 71% Fade: 74% Thesis Break: 58% Today: 0.48 - 0.64	Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial Parse: PARSED	BARDA released $29M and enabled near-term sentinel data, but reduced total award and OTC microcap quality raise pop-and-fade risk. Input: ADEQUATE - News is actionable with clear funding and data-timing details, though live volume and balance-sheet context are limited.
2026-06-25 12:01:45 Story: 2026-06-25 08:00:00	LYEL ID 1735	UNCERTAIN Up 8% / Down 6%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 10% Fade: 85% Thesis Break: 4% Today: 12.40 - 13.40	Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference Parse: PARSED	Conference participation is routine and contains no new clinical, regulatory, financing, or partnership catalyst likely to drive durable repricing. Input: ADEQUATE - Enough context is provided to classify this as non-actionable routine investor conference news.
2026-06-25 11:45:24 Story: 2026-06-25 07:45:00	VBIO ID 1734	UP Up 62% / Down 28%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_UP PRECLINICAL PRNewswire RSS	Reprice: 71% Fade: 86% Thesis Break: 74% Today: 0.49 - 0.72	AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS Parse: PARSED	Protocol finalization with AFRRI/NIAID is a concrete derisking step, but this tiny distressed microcap still carries extreme pop-and-fade risk. Input: ADEQUATE - News is fresh and specific, with enough market-cap and prior-news context to judge likely reaction quality.
2026-06-25 11:32:16 Story: 2026-06-25 07:30:00	PSTV ID 1733	UP Up 72% / Down 28%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_UP PARTNERSHIP GlobeNewswire RSS	Reprice: 74% Fade: 79% Thesis Break: 41% Today: 3.70 - 5.10	Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer Parse: PARSED	National payer coverage with Elevance materially expands reimbursable access, but PSTV remains a fragile microcap prone to pop-and-fade reactions. Input: ADEQUATE - Fresh headline, market cap, short interest, and recent similar coverage context are sufficient for an event-reaction judgment.
2026-06-25 11:32:11 Story: 2026-06-25 07:30:00	BCTX ID 1732	UNCERTAIN Up 28% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS PARTNERSHIP GlobeNewswire RSS	Reprice: 31% Fade: 82% Thesis Break: 12% Today: 2.85 - 3.45	BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™ Parse: PARSED	Non-binding commercial-readiness MoU adds little near-term value and lacks clinical, regulatory, or financial substance. Input: ADEQUATE - Story details and recent financing context are sufficient to judge this as low-urgency routine partnership news.
2026-06-25 11:32:06 Story: 2026-06-25 07:30:00	VANI ID 1731	UP Up 68% / Down 24%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_UP REGULATORY GlobeNewswire RSS	Reprice: 61% Fade: 72% Thesis Break: 58% Today: 1.16 - 1.38	Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management Parse: PARSED	Phase 1 trial-initiation approval in obesity is a real catalyst, but tiny size and early stage make any spike vulnerable to fading. Input: ADEQUATE - News, market cap, liquidity, price history, and insider context are sufficient for short-horizon event-reaction assessment.
2026-06-25 11:02:39 Story: 2026-06-25 07:00:00	TLSA ID 1730	UNCERTAIN Up 41% / Down 22%	Fish: YES Chart: YES MEDIUM	WATCH_CHART OTHER GlobeNewswire RSS	Reprice: 46% Fade: 78% Thesis Break: 18% Today: 1.07 - 1.28	Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial Parse: PARSED	Last-patient-dosed advances timeline to topline data, but this is a known operational milestone and likely a low-quality microcap pop. Input: ADEQUATE - News, price history, and recent catalyst context are sufficient to judge this as monitor-worthy but not a strong standalone repricing event.
2026-06-25 11:02:32 Story: 2026-06-25 07:00:00	MCRB ID 1729	UP Up 58% / Down 22%	Fish: YES Chart: YES MEDIUM	WATCH_CHART CLINICAL_DATA GlobeNewswire RSS	Reprice: 61% Fade: 74% Thesis Break: 68% Today: 6.45 - 7.85	Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis Parse: PARSED	Scheduled top-line SER-155 clinical results create near-term catalyst attention, but this is only a webcast announcement and likely a fragile pop. Input: ADEQUATE - Enough context exists to judge this as catalyst-setting news, though actual readout quality remains unknown until July 8.
2026-06-25 11:02:26 Story: 2026-06-25 07:00:00	INMB ID 1728	UP Up 63% / Down 24%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_UP REGULATORY GlobeNewswire RSS	Reprice: 58% Fade: 72% Thesis Break: 41% Today: 1.28 - 1.58	INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™ Parse: PARSED	MHRA PIP approval modestly de-risks the UK filing path, but it follows similar recent alignment news and likely carries high pop-and-fade risk. Input: ADEQUATE - Enough context exists to judge this as incremental regulatory progress rather than a major standalone approval catalyst.
2026-06-25 11:02:21 Story: 2026-06-25 07:00:00	KYMR ID 1727	UP Up 68% / Down 22%	Fish: YES Chart: YES MEDIUM	WATCH_CHART OTHER GlobeNewswire RSS	Reprice: 61% Fade: 58% Thesis Break: 24% Today: 96.00 - 104.00	Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026 Parse: PARSED	Early Phase 2b enrollment completion advances a meaningful topline catalyst, but no new efficacy data limits immediate repricing magnitude. Input: ADEQUATE - News, price context, short interest, and insider activity are sufficient to judge near-term event reaction risk.
2026-06-25 11:01:11 Story: 2026-06-25 07:00:00	NUVB ID 1726	DOWN Up 20% / Down 78%	Fish: YES Chart: YES HIGH	STRAY_WILDCAT_DOWN FINANCING PRNewswire RSS	Reprice: 86% Fade: 42% Thesis Break: 34% Today: 5.55 - 6.65	Nuvation Bio Announces Proposed Convertible Senior Notes Offering Parse: PARSED	Proposed $200M convertible notes usually pressure biotech shares via dilution and financing overhang, despite debt repayment and capped call mitigation. Input: ADEQUATE - Fresh financing terms, market cap, short interest, and recent momentum are sufficient for event-reaction assessment.
2026-06-25 10:37:05 Story: 2026-06-25 06:35:00	PRQR ID 1725	DOWN Up 22% / Down 82%	Fish: YES Chart: YES HIGH	STRAY_WILDCAT_DOWN FINANCING GlobeNewswire RSS	Reprice: 88% Fade: 41% Thesis Break: 34% Today: 1.62 - 1.89	ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement Parse: PARSED	Large discounted equity raise signals dilution, though Lilly participation softens balance-sheet stress and limits thesis damage. Input: ADEQUATE - Fresh financing terms, pricing, market cap, and recent catalyst context are sufficient for event-reaction assessment.
2026-06-25 10:11:57 Story: 2026-06-25 06:10:00	TECH ID 1724	UP Up 96% / Down 8%	Fish: YES Chart: YES HIGH	STRAY_WILDCAT_UP OTHER PRNewswire RSS	Reprice: 99% Fade: 12% Thesis Break: 18% Today: 68.00 - 73.00	Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets Parse: PARSED	Definitive all-cash acquisition at $73 per share creates immediate takeover repricing toward deal value with limited fade risk. Input: ADEQUATE - Headline and body provide definitive terms, premium, financing, and expected close timing sufficient for event-reaction assessment.
2026-06-25 10:02:07 Story: 2026-06-25 06:00:00	ATAI ID 1723	UP Up 58% / Down 18%	Fish: YES Chart: YES MEDIUM	WATCH_CHART OTHER GlobeNewswire RSS	Reprice: 46% Fade: 62% Thesis Break: 12% Today: 4.02 - 4.45	AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets Parse: PARSED	Russell inclusion can drive short-term passive-flow demand and visibility, but this is usually a modest, event-driven move with meaningful fade risk. Input: ADEQUATE - News, liquidity, market cap, and recent price context are sufficient for a short-horizon event-reaction assessment.
2026-06-25 08:53:00 Story: 2026-06-25 04:52:00	IMMP ID 1722	DOWN Up 3% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 8% Fade: 96% Thesis Break: 6% Today: 0.37 - 0.40	Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP Parse: PARSED	Repeat shareholder lawsuit notice after prior identical alerts, with little new catalyst content and limited incremental repricing impact. Input: ADEQUATE - Recent headline history clearly shows this is recycled legal advertising rather than fresh fundamental news.
2026-06-25 08:02:20 Story: 2026-06-25 04:01:00	ADMA ID 1721	DOWN Up 5% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 8% Fade: 92% Thesis Break: 12% Today: 8.35 - 8.85	ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA Parse: PARSED	Repeat plaintiff-lawyer class action notice is stale, non-operational news and usually adds little incremental repricing after the initial disclosure. Input: ADEQUATE - Recent headline history clearly shows this is repetitive lawsuit solicitation rather than a fresh company catalyst.
2026-06-25 08:01:09 Story: 2026-06-24 20:40:00	CMPX ID 1720	UNCERTAIN Up 1% / Down 1%	Fish: NO Chart: NO HIGH	IGNORE OTHER PRNewswire RSS	Reprice: 2% Fade: 95% Thesis Break: 0% Today: 1.98 - 2.05	Jocelyn Freimuth and Camino Compass to Lead First-Ever Qualified Evaluator Workshop at Compounding360 Studio Sessions Parse: PARSED	PRNewswire item is unrelated ticker-noise about a pharmacy workshop, not a Compass Therapeutics catalyst. Input: ADEQUATE - Story clearly appears mismatched to CMPX and contains no company-specific biotech, financing, or regulatory catalyst.
2026-06-25 08:01:03 Story: 2026-06-25 02:00:00	GPCR ID 1719	UNCERTAIN Up 1% / Down 1%	Fish: NO Chart: NO HIGH	IGNORE OTHER GlobeNewswire RSS	Reprice: 2% Fade: 0% Thesis Break: 0% Today: 47.80 - 48.50	Copenhagen Infrastructure Partners reaches financial close on Pestera II onshore wind farm in Romania Parse: PARSED	Story is unrelated to Structure Therapeutics and concerns renewable infrastructure, so it should not drive biotech repricing in GPCR. Input: ADEQUATE - Headline-body mismatch is clear enough to classify this as irrelevant ticker noise.
2026-06-25 08:00:58 Story: 2026-06-24 20:59:00	MESO ID 1718	UP Up 68% / Down 22%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_UP FINANCING GlobeNewswire RSS	Reprice: 61% Fade: 34% Thesis Break: 18% Today: 15.10 - 16.35	Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility Parse: PARSED	Non-dilutive five-year funding that retires costly near-term debt improves runway and balance-sheet flexibility, supporting modest positive repricing attention. Input: ADEQUATE - News, balance-sheet details, market cap, liquidity, and recent context are sufficient for short-horizon event-reaction assessment.
2026-06-25 08:00:48 Story: 2026-06-24 22:33:00	TSHA ID 1717	DOWN Up 18% / Down 84%	Fish: YES Chart: YES HIGH	STRAY_WILDCAT_DOWN FINANCING GlobeNewswire RSS	Reprice: 88% Fade: 42% Thesis Break: 28% Today: 5.75 - 6.20	Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants Parse: PARSED	Large discounted equity offering near market price creates immediate dilution and usually pressures biotech shares despite strengthening cash runway. Input: ADEQUATE - Offering size, price, market cap, float, and recent catalyst context are sufficient for short-term event-reaction assessment.
2026-06-25 08:00:42 Story: 2026-06-25 01:00:00	ADXN ID 1716	DOWN Up 18% / Down 62%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN EARNINGS GlobeNewswire RSS	Reprice: 41% Fade: 74% Thesis Break: 71% Today: 5.55 - 6.35	Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Parse: PARSED	Routine earnings update highlights very low cash and only future data timing, creating financing overhang and downside attention. Input: ADEQUATE - News and market context are sufficient to assess near-term reaction risk.
2026-06-24 23:33:09 Story: 2026-06-24 19:31:00	RVMD ID 1715	UNCERTAIN Up 38% / Down 18%	Fish: NO Chart: YES MEDIUM	WATCH_CHART CLINICAL_DATA GlobeNewswire RSS	Reprice: 34% Fade: 62% Thesis Break: 8% Today: 165.00 - 173.00	Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 Parse: PARSED	Conference presentation notice signals near-term data visibility, but it is scheduled and largely preview-style rather than a fresh efficacy surprise. Input: ADEQUATE - Enough context exists to judge this as watchlist-worthy but not a high-urgency repricing catalyst by itself.
2026-06-24 22:04:30 Story: 2026-06-24 18:03:00	ADMA ID 1714	UNCERTAIN Up 5% / Down 15%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 10% Fade: 95% Thesis Break: 20% Today: 8.45 - 8.85	ADMA Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages ADMA Investors with Losses to Contact the Firm Parse: PARSED	Another plaintiff-law-firm class-action alert repeats known allegations and usually adds little new price-discovery after the March collapse. Input: ADEQUATE - Recent headline history clearly shows this is repetitive lawsuit solicitation, not a fresh operational or regulatory catalyst.
2026-06-24 22:01:09 Story: 2026-06-24 18:00:00	IRON ID 1713	UNCERTAIN Up 5% / Down 18%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER PRNewswire RSS	Reprice: 12% Fade: 85% Thesis Break: 10% Today: 68.80 - 71.50	Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Parse: PARSED	Law firm investigation repeats already known CRL fallout and rarely creates fresh standalone repricing in a large-cap biotech. Input: ADEQUATE - Recent context shows this same investigation headline already appeared, reducing novelty and immediate catalyst value.
2026-06-24 20:18:10 Story: 2026-06-24 16:16:00	CMPX ID 1712	UNCERTAIN Up 1% / Down 1%	Fish: NO Chart: NO HIGH	IGNORE OTHER PRNewswire RSS	Reprice: 2% Fade: 95% Thesis Break: 0% Today: 2.00 - 2.03	Compass Working Capital Celebrates Passage of Pilot Program to Strengthen Asset-Building Initiative in Bipartisan Housing Bill Parse: PARSED	Story concerns an unrelated nonprofit named Compass Working Capital, not Compass Therapeutics, so it is non-catalyst ticker noise. Input: ADEQUATE - Enough context to identify this as a false ticker-match headline with no biotech relevance.
2026-06-24 20:16:55 Story: 2026-06-24 16:15:00	APLM ID 1711	DOWN Up 22% / Down 74%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN COMPLIANCE GlobeNewswire RSS	Reprice: 71% Fade: 63% Thesis Break: 78% Today: 18.20 - 21.40	Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia Parse: PARSED	Nasdaq MVLS deficiency and failed partner payment outweigh regained Asia rights, raising delisting and financing-risk repricing pressure. Input: ADEQUATE - News, market cap, float, financing context, and prior listing history are sufficient for short-term event-reaction assessment.
2026-06-24 20:07:00 Story: 2026-06-24 16:05:00	PASG ID 1710	DOWN Up 28% / Down 82%	Fish: YES Chart: YES HIGH	STRAY_WILDCAT_DOWN OTHER GlobeNewswire RSS	Reprice: 91% Fade: 74% Thesis Break: 88% Today: 4.80 - 6.80	Passage Bio and Remix Therapeutics Announce Merger Agreement Parse: PARSED	Reverse-merger terms leave PASG holders with only about 7%, signaling shell-value repricing despite the large financing and new pipeline narrative. Input: ADEQUATE - Merger ownership split, financing size, runway, and microcap float provide enough context for near-term event-reaction assessment.
2026-06-24 20:06:54 Story: 2026-06-24 16:05:00	SPRY ID 1709	DOWN Up 22% / Down 64%	Fish: YES Chart: YES MEDIUM	STRAY_WILDCAT_DOWN OTHER GlobeNewswire RSS	Reprice: 58% Fade: 41% Thesis Break: 52% Today: 9.85 - 10.85	ARS Pharmaceuticals Provides Commercial and Financial Updates Parse: PARSED	No July formulary additions undercuts near-term neffy access expectations, while expense cuts and 2027 breakeven guidance only partly offset the commercial disappointment. Input: ADEQUATE - News, balance-sheet context, short interest, and recent catalyst history are sufficient for an event-reaction judgment.
2026-06-24 20:05:47 Story: 2026-06-24 16:05:00	IPSC ID 1708	UNCERTAIN Up 1% / Down 1%	Fish: NO Chart: NO HIGH	IGNORE EARNINGS PRNewswire RSS	Reprice: 2% Fade: 95% Thesis Break: 0% Today: 2.28 - 2.31	Century Communities Sets Date for Second Quarter 2026 Earnings Release and Conference Call Parse: PARSED	Story is unrelated ticker-mismatch routine earnings scheduling for homebuilder CCS, not a biotech catalyst for IPSC. Input: ADEQUATE - News clearly references Century Communities, so no actionable IPSC repricing signal is present.
2026-06-24 20:02:17 Story: 2026-06-24 16:01:00	TSHA ID 1707	DOWN Up 12% / Down 86%	Fish: YES Chart: YES HIGH	STRAY_WILDCAT_DOWN FINANCING GlobeNewswire RSS	Reprice: 91% Fade: 38% Thesis Break: 24% Today: 5.95 - 6.95	Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Parse: PARSED	Proposed $200M equity offering is materially dilutive and likely pressures shares after a recent catalyst-driven run-up. Input: ADEQUATE - News, valuation, recent momentum, and capital structure context are sufficient for a short-horizon event-reaction call.
2026-06-24 20:02:11 Story: 2026-06-24 16:01:00	KYMR ID 1706	UNCERTAIN Up 12% / Down 10%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 14% Fade: 78% Thesis Break: 4% Today: 97.50 - 101.50	Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors Parse: PARSED	Board chair succession is governance news without clinical, regulatory, financing, or partnership substance, so immediate repricing risk appears limited. Input: ADEQUATE - News, price context, and recent catalysts are sufficient to classify this as low-urgency routine governance news.
2026-06-24 19:54:34 Story: 2026-06-24 15:54:00	ARWR ID 1705	UNCERTAIN Up 1% / Down 1%	Fish: NO Chart: NO HIGH	IGNORE OTHER PRNewswire RSS	Reprice: 1% Fade: 99% Thesis Break: 0% Today: 79.70 - 79.95	Mercedes-Benz of Arrowhead Invites Drivers to Experience the Mercedes-Benz GLC 300 Through Complimentary Test Drives Parse: PARSED	PRNewswire item is unrelated dealership advertising, not Arrowhead Pharmaceuticals catalyst news. Input: ADEQUATE - Ticker-news mismatch is clear and no biotech repricing catalyst is present.
2026-06-24 13:07:51 Story: 2026-06-24 09:06:00	APLT ID 1704	UNCERTAIN Up 28% / Down 12%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS PRECLINICAL GlobeNewswire RSS	Reprice: 24% Fade: 86% Thesis Break: 18% Today: -	Applied Biologics Announces Completion of Translational Research Supporting the Biologic Performance of XWRAP® Parse: PARSED	Rodent translational support for XWRAP is incremental, non-pivotal, and likely overshadowed by prior clinical updates and ticker-quality confusion. Input: ADEQUATE - Story is clear enough: preclinical comparator data without regulatory, financing, or definitive human efficacy catalyst.
2026-06-24 13:02:21 Story: 2026-06-24 09:00:00	GPCR ID 1703	UNCERTAIN Up 1% / Down 1%	Fish: NO Chart: NO HIGH	IGNORE FINANCING PRNewswire RSS	Reprice: 2% Fade: 95% Thesis Break: 0% Today: 45.20 - 45.90	Terawatt Infrastructure secures $300M in secured debt financing to expand its full-stack autonomous vehicle infrastructure platform Parse: PARSED	Story concerns Terawatt Infrastructure, not GPCR, so it is non-company news with negligible repricing relevance. Input: ADEQUATE - Ticker-news mismatch is clear enough to classify this as irrelevant for GPCR monitoring.
2026-06-24 13:02:14 Story: 2026-06-24 09:00:00	VRAX ID 1702	DOWN Up 12% / Down 78%	Fish: YES Chart: YES HIGH	STRAY_WILDCAT_DOWN COMPLIANCE PRNewswire RSS	Reprice: 74% Fade: 88% Thesis Break: 72% Today: 0.13 - 0.17	Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation Parse: PARSED	1-for-25 reverse split to regain Nasdaq compliance is typically bearish for fragile microcaps and often precedes dilution or continued weakness. Input: ADEQUATE - News, market cap, price trend, and compliance motive are sufficient to assess near-term downside repricing risk.
2026-06-24 12:49:08 Story: 2026-06-24 08:48:00	ACTU ID 1701	UNCERTAIN Up 4% / Down 2%	Fish: NO Chart: NO HIGH	IGNORE OTHER PRNewswire RSS	Reprice: 5% Fade: 92% Thesis Break: 1% Today: 1.86 - 2.02	Actuate Named a 2026 Colorado Companies to Watch Winner Parse: PARSED	This is a non-material local award and appears unrelated to the biotech issuer’s core clinical or financial catalyst path. Input: ADEQUATE - The story is clearly non-catalytic and likely mismatched to the public biotech ticker.
2026-06-24 12:46:44 Story: 2026-06-24 08:45:00	NTHI ID 1700	UNCERTAIN Up 42% / Down 28%	Fish: YES Chart: YES MEDIUM	WATCH_CHART OTHER GlobeNewswire RSS	Reprice: 46% Fade: 84% Thesis Break: 71% Today: 4.45 - 5.75	NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum Parse: PARSED	Paid promotional rehash of already announced UAE IND news may spark low-float attention, but concrete new value creation appears limited. Input: ADEQUATE - Recent headline history clearly shows this story largely repeats prior catalyst news and adds promotional framing rather than a fresh fundamental development.
2026-06-24 12:41:08 Story: 2026-06-24 08:38:00	PHGE ID 1699	UNCERTAIN Up 18% / Down 22%	Fish: NO Chart: NO HIGH	ROUTINE_NEWS OTHER GlobeNewswire RSS	Reprice: 20% Fade: 91% Thesis Break: 84% Today: 0.41 - 0.52	BiomX: Next-Gen Counter Drone Solutions will be Showcased by DFSL at ISC 2026 Parse: PARSED	Trade-show showcase lacks contract, revenue, regulatory, or financing catalyst and reads like promotional portfolio messaging. Input: ADEQUATE - News, price action, compliance risk, and financing context are sufficient to judge this as low-urgency routine news.
2026-06-24 12:38:49 Story: 2026-06-24 08:37:00	RCKT ID 1698	UNCERTAIN Up 38% / Down 18%	Fish: YES Chart: YES MEDIUM	WATCH_CHART COMPLIANCE PRNewswire RSS	Reprice: 41% Fade: 82% Thesis Break: 71% Today: 3.30 - 3.75	Rocket One Regains Full Nasdaq Compliance with Minimum Bid Price Requirement Parse: PARSED	Nasdaq compliance removal reduces delisting overhang, but this is usually a low-quality microcap headline prone to brief pop-and-fade behavior. Input: ADEQUATE - Fresh compliance news, short interest, price history, and recent promotional context are sufficient for an event-reaction judgment.

Instant Intelligence for Biotech Investors

ScanScor WCFF Events